Questcor Pharma (QCOR) Issues Preliminary Q3 Operating Metrics; Sees Acthar Vial Shipments Up 45%
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Join SI Premium – FREE
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), reports the following preliminary third-quarter operating metrics.
Based on internal Company data through September 26, 2011:
Based on internal Company data through September 26, 2011:
- New, paid prescriptions of the Company's principal drug, H.P. Acthar® Gel (Acthar), for the treatment of exacerbations of multiple sclerosis (MS) during the full third quarter are expected to exceed 850, up over 160% from the year ago period.
- New, paid prescriptions for nephrotic syndrome (NS) are expected to exceed 55.
- New, paid prescriptions for infantile spasms (IS) are expected to exceed 105.
- Vials of Acthar, shipped during the quarter are expected to exceed 2,750, up over 45% from the year ago period.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
Create E-mail Alert Related Categories
FDA, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
